SCHEMBL149316

SCHEMBL149316

Cc1ccc([N+](=O)[O-])c(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DTYMK P23919 1/20 0.62
TSHR P16473 5/20 0.60
CYP3A4 P08684 1/20 0.60
CSNK2A1 P68400 1/20 0.53
CASP6 P55212 1/20 0.50
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 1/20 0.46
GPR35 Q9HC97 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935450 1.00 DTYMK (0.62) DTYMKTSHRCYP3A4CSNK2A1CASP6
Potassium Ion SCHEMBL11048083 0.98 DTYMK (0.60) DTYMKTSHRCYP3A4CSNK2A1CASP6
SCHEMBL11048087 0.98 DTYMK (0.60) DTYMKTSHRCYP3A4CSNK2A1CASP6
SCHEMBL8446509 0.98 DTYMK (0.60) DTYMKTSHRCYP3A4CSNK2A1CASP6
Hydrochloric Acid SCHEMBL3730916 0.98 DTYMK (0.60) DTYMKTSHRCYP3A4CSNK2A1CASP6
SCHEMBL295645 0.89 DTYMK (0.51) DTYMKTSHRCYP3A4CSNK2A1MEN1
SCHEMBL28395903 0.87 TSHR (0.62) DTYMKTSHRCYP3A4POLBALDH1A1
SCHEMBL9215380 0.86 POLB (0.59) DTYMKTSHRCYP3A4MEN1POLB
SCHEMBL406111 0.85 TSHR (0.60) DTYMKTSHRCYP3A4CSNK2A1CASP6
SCHEMBL1277039 0.85 TSHR (0.60) DTYMKTSHRCYP3A4POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
CN-120192230-A Method for treating nitrobenzoic acid mixture as byproduct of 3-methyl-2-nitrobenzoic acid 南昌大学 2025-06-24 CN claimed
CN-119080334-A Comprehensive utilization method of nitric acid containing organic matters 山东友道化学有限公司 2024-12-06 CN claimed
CN-118344743-B High-viscosity modified asphalt and preparation method thereof 南京航空航天大学 2024-11-26 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-118388359-A Preparation method of ethyl 5-methyl-2-aminobenzoate 江西大宇医药股份有限公司 2024-07-26 CN claimed
CN-118344743-A High-viscosity modified asphalt and preparation method thereof 南京航空航天大学 2024-07-16 CN claimed
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 CN claimed
CN-112441926-B Method for co-producing m-methylbenzoic acid nitride and m-phthalic acid 山东友道化学有限公司 2022-10-14 CN claimed
CN-112441926-A Method for co-producing m-methylbenzoic acid nitride and m-phthalic acid 山东有言环保科技有限公司 2021-03-05 CN claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-0902683-A1 AGONISTS IN THE COSTIMULATION OF TcR/CD3-INDUCED T-LYMPHOCYTES RADOPATH LIMITED (GB) 1999-03-24 EP claimed
WO-1997034593-A1 AGONISTS IN THE COSTIMULATION OF TcR/CD3-INDUCED T-LYMPHOCYTES RADOPATH LIMITED (GB) 1997-09-25 WO claimed
US-4005145-A ISOMERIZATION OF A,B-UNSATURATED OXO COMPOUNDS TO B,G-ISOMER HOFFMANN-LA ROCHE INC. (US) 1977-01-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 DTYMK 3866/4885TSHR 2894/4885CYP3A4 797/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 DTYMK 627/4885TSHR 4082/4885CYP3A4 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.